Class Action Lawsuit Against Soleno Therapeutics: Investors Urged to Act Now

Investor Alert: Legal Action Against Soleno Therapeutics

Pomerantz LLP, a prominent law firm known for its expertise in corporate and securities class action lawsuits, has officially announced that a class action lawsuit has been initiated against Soleno Therapeutics, Inc., trading on NASDAQ under the ticker SLNO. The lawsuit aims to address potential securities fraud or unlawful business practices by the company and certain key executives.

Background

The suit comes in light of alarming claims regarding Soleno's only product, the diazoxide choline extended-release tablets, commonly referred to as DCCR. In an August 2025 report by Scorpion Capital, DCCR was described as both overpriced and potentially unsafe for children. This report raised concerns among investors, leading to a significant drop in Soleno’s stock price.

On August 15, 2025, following the publication of the Scorpion report, Soleno’s stock fell by $5.73, representing a 7.41% decline. The downward trend continued when on September 10, 2025, the company disclosed a troubling incident where a patient died after taking DCCR. This news caused Soleno's share price to plunge by $13.49, a striking 19.21% drop, over the next two trading days.

The turbulence surrounding Soleno did not stop there. During a quarterly earnings call on November 4, 2025, the company revealed alarming statistics about DCCR's discontinuation rate due to adverse effects, reported to be approximately 8% at the end of the third quarter of 2025. According to the company’s CEO, the negative publicity from the Scorpion report disrupted DCCR's launch trajectory, resulting in fewer patient start forms and increased discontinuations. This led to another steep decline in the stock value, with a decrease of $16.98 or 26.59%, closing at $46.87 on November 5, 2025.

Call to Action for Investors

Investors who have incurred losses due to their investment in Soleno during the class period are advised to act quickly. They can participate by contacting Danielle Peyton from Pomerantz LLP at 646-581-9980 or via email at [email protected] It is urged that inquiries include a mailing address, phone number, and details of the number of shares purchased. Investors have until May 5, 2026, to request to be appointed as Lead Plaintiff in this class action.

The Pomerantz team specializes in protecting the rights of investors and fighting against corporate malpractices. With over 85 years of experience in the field, Pomerantz has secured numerous multimillion-dollar recoveries for victims of securities fraud and corporate misconduct. Detailed documentation about this class action, including the Complaint, is available online at Pomerantz Law Firm’s website.

Conclusion

For those who have invested in Soleno Therapeutics, this lawsuit represents a vital opportunity to seek redress for potential losses incurred due to alleged fraud. The legal team at Pomerantz is committed to providing robust representation for affected investors, making it critical for those interested to connect swiftly before the deadlines arrive. With the backdrop of ongoing investigations and legal scrutiny, the situation surrounding Soleno Therapeutics serves as a poignant reminder of the risks associated with investing in volatile markets, particularly in the pharmaceutical sector, where patient safety can profoundly impact stock performance.